|
Nov 12
|
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
|
|
Nov 8
|
Guardant Health Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
|
|
Nov 7
|
Guardant Health Pops 13% On An 'Impressive' Beat Following Exact Sciences' Flop
|
|
Nov 7
|
Guardant Health Inc (GH) Q3 2024 Earnings Call Highlights: Record Revenue Growth and Strategic ...
|
|
Nov 7
|
Guardant Health (GH) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
|
|
Nov 6
|
Guardant Health (GH) Reports Q3 Loss, Tops Revenue Estimates
|
|
Nov 6
|
Guardant Health: Q3 Earnings Snapshot
|
|
Aug 27
|
Guardant Health to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
|
|
Aug 26
|
Midday movers: PDD Holdings, NVIDIA fall; Xpeng gains
|
|
Aug 26
|
Why Guardant Health Stock Just Crashed 10%
|
|
Jul 29
|
FDA approves Guardant Health's blood test for colon cancer
|
|
Jul 29
|
Guardant Health Gets FDA Nod on Colorectal Cancer Blood Test
|
|
Jul 29
|
Guardant wins FDA approval for colon cancer blood test
|
|
Jul 29
|
Guardant Health’s Shield™ Blood Test Approved by FDA as a Primary Screening Option, Clearing Path for Medicare Reimbursement and a New Era of Colorectal Cancer Screening
|
|
Jul 24
|
Guardant Health to Report Second Quarter 2024 Financial Results on August 7, 2024
|
|
Jul 23
|
Guardant Health Introduces Major Smart Liquid Biopsy Upgrade to Market-Leading Guardant360® Test, Further Extending Its Best-in-Class Performance
|
|
Jul 23
|
Guardant settles allegations it violated the False Claims Act
|
|
Jun 26
|
Guardant Health (GH) Just Overtook the 20-Day Moving Average
|
|
Jun 25
|
Guardant Health (GH) Now Trades Above Golden Cross: Time to Buy?
|
|
May 16
|
Guardant Health to present real-world data supporting performance of Shield™ blood test for colorectal cancer screening at 2024 Digestive Disease Week
|